Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatments [Seeking Alpha]
VistaGen Therapeutics, Inc. (VTGN)
Last vistagen therapeutics, inc. earnings: 2/13 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vistagen.com
Company Research
Source: Seeking Alpha
Fasedienol has advantages as a non-systemic, low-abuse anxiolytic and is seeking Breakthrough Therapy Designation. VTGN's diverse product pipeline includes treatments for social anxiety disorders, major depressive disorder, menopause symptoms, and more. My valuation analysis suggests a strong cash position with a solid runway to support its FDA trials. It currently trades below cash value, making VTGN stock exceedingly compelling. Despite regulatory, market adoption, and potential stock dilution risks, VTGN's prospects are remarkably promising, supporting my "buy" rating. VistaGen Therapeutics, Inc. ( NASDAQ: VTGN ), established in 1998 and headquartered in South San Francisco, California, is developing a pipeline of Central Nervous System [CNS] drugs with the potential to innovate the treatment for serious anxiety, depression, and other CNS disorders. VTGN's lead candidate, Fasedienol [PH94B], is progressing in phase 3 of the clinical trials, and it presents advantages over
Show less
Read more
Impact Snapshot
Event Time:
VTGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTGN alerts
High impacting VistaGen Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VTGN
News
- Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental FatigueBusiness Wire
- Vistagen Therapeutics: A Pipeline With Potential In Anxiety And Depression [Seeking Alpha]Seeking Alpha
- Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) ConferenceBusiness Wire
- Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2Business Wire
- Vistagen Therapeutics: Initial Analysis Of Fasedienol Points To Bullish [Seeking Alpha]Seeking Alpha
VTGN
Earnings
- 2/13/24 - Beat
VTGN
Sec Filings
- 4/26/24 - Form 8-K
- 4/16/24 - Form DEF
- 4/5/24 - Form PRE
- VTGN's page on the SEC website